CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPS

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings data on Monday. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06), Briefing.com reports. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same period last year, the firm earned ($0.98) earnings per share. The business’s revenue for the quarter was down 99.3% compared to the same quarter last year.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP traded down $0.64 during mid-day trading on Wednesday, hitting $48.69. 500,100 shares of the stock were exchanged, compared to its average volume of 1,595,276. The firm’s 50-day simple moving average is $56.97 and its 200 day simple moving average is $63.10. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of -17.99 and a beta of 1.70.

Insider Buying and Selling

In other news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CRSP shares. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Piper Sandler restated an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Robert W. Baird increased their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price for the company. Finally, Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $73.31.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.